Mackenzie G. .2016 .The definition and classification of pneumonia. Pneumonia (Nathan), 8 : 14.
Khaky B,Yazdannik A,Mahjoubipour H,Attari F. .2018 .The Effect of Oral Decontamination Plan on The Occurrence Of Ventilator Associated Pneumonia in Icu Patients: A Double-Blind Clinical Trial. , 6(1) : 12-6.
Qusti SY,Alseeni MN,Alharbi RA,Balgoon M,Jambi EJ,Alotaibi SA .2018 .Antibacterial Activity of Selected Plants Species Extract Cited in the Holy Quran Against Clinical Isolates. Pharmacophores, 9(5) : 18-28.
Mahendra M,Jayaraj BS,Limaye S,Chaya SK,Dhar R,Mahesh PA .2018 .Factors influencing severity of community-acquired pneumonia. Lung India, 35(4) : 284-289.
Thoracic American,Society American .2005 .Infectious Diseases of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 171(4) : 388-416.
Feldman C,Anderson R .2016 .The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia. Semin Respir Crit Care Med, 37(6) : 806-818.
Forstner C,Rohde G,Rupp J .2016 .Community-acquired Haemophilus influenzae pneumonia--New insights from the CAPNETZ study. J Infect, 72(5) : 554-563.
Ariza-Prota MA,Pando-Sandoval A,García-Clemente M,FoleVázquez D .2016 .Community-Acquired Moraxella catarrhalis Bacteremic Pneumonia: Two Case Reports and Review of the Literature. Case Rep Pulmonol, : 5134969.
Ahamed Thanish,Lakshmi S,Antibacterial T. .2018 .Activity of Taxifolin Isolated from Acacia Catechu Leaf Extract-An in Vitro Study. Int. J. Pharm. Res. Allied Sci, 7(4) : 133-7.
Henriques-Normark B,Tuomanen EI .2013 .The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring HarbPerspect Med, 3(7) : a010215.
Dion CF,Ashurst JV,Island (FL): StatPearls Publishing JV . .. Streptococcus Pneumoniae. [Updated 2020 Mar, 25 : .
Cherazard R,Epstein M,Doan TL,Salim T,Bharti S,Smith MA .2017 .Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Ther, 24(3) : e361-e369.
Tristram S,Jacobs MR,Appelbaum PC .2007 .Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev, 20(2) : 368-89.
Mojgani N,Rahbar M,Taqizadeh M,Ashtiani MP,Mohammadzadeh M .2011 .Biotyping, capsular typing, and antibiotic resistance pattern of Haemophilus influenzae strains in Iran. Japan J Infect Dis, 64(1) : 66-8.
Li XX,Xiao SZ,Gu FF,He WP,Ni YX,Han LZ .2020 .Molecular Epidemiology and Antimicrobial Resistance of Haemophilus influenzae in Adult Patients in Shanghai, China. , 8 : 95.
Hare KM,Seib KL,Chang AB,Harris TM,Spargo JC,SmithVaughan HC .2019 .Antimicrobial susceptibility and impact of macrolide antibiotics on Moraxella catarrhalis in the upper and lower airways of children with chronic endobronchial suppuration. J Med Microbiol, 68(8) : 1140-1147.
Liu Y,Xu H,Xu Z .2015 .High-Level Macrolide-Resistant Moraxella catarrhalis and Development of an Allele-Specific PCR Assay for Detection of 23S rRNA Gene A2330T Mutation: A Three-Year Study at a Chinese Tertiary Hospital. Microb Drug Resist, 21(5) : 507-511.
Du Y,Zhou H,Wang F .2017 .Multilocus sequence typing-based analysis of Moraxella catarrhalis population structure reveals clonal spreading of drug-resistant strains isolated from childhood pneumonia. Infect Genet Evol, 56 : 117-124.
Lhommet C,Garot D,Grammatico-Guillon L .2020 .Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?. BMC Pulm Med, 20(1) : 62.
Randhawa MA,Bawadekji A,Al Ali M,Oueslati MH,Basha JW,Including MRSA .2018 .Multidrug Resistant Acinetobacter Baumannii. Int. J. Pharm. Phytopharm. Res, 8(4) : 1-5.
Perry W,Golan Y .2019 .Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia. Future Microbiol, 14 : 927-939.
Rodvold KA .2019 .Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother, 74(Suppl 3) : iii2-iii4.
Paukner S,Riedl R .2017 .Potent Drugs for Resistant BugsMode of Action and Resistance. Cold Spring HarbPerspect Med, 7(1) : a027110.
Eyal Z,Matzov D,Krupkin M .2016 .Published 2016 Dec 13. Sci Rep, 6 : 39004.
Birch AJ,Holzapfel CW,Richards RW .1963 .Diterpenoid nature of pleuromutilin. Chem Ind, 5 : 374-375.
Lin J,Zhou D,Steitz TA,Polikanov YS,Gagnon MG .2018 .RibosomeTargeting Antibiotics: Modes of Action, Mechanisms of Resistance, and Implications for Drug Design. Annu Rev Biochem, 87 : 451-478.
Wicha WW,Prince WT,Lell C,Heilmayer W,Gelone SP .2019 .Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother, 74(Suppl 3) : iii19-iii26.
Paukner S,Sader HS,Ivezic-Schoenfeld Z,Jones RN .2013 .Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother, 57 : 4489e95.
Sader HS,Paukner S,Ivezic-Schoenfeld Z,Biedenbach DJ,Schmitz FJ,Jones RN .2012 .Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for communityacquired respiratory tract infections (CARTIs). J Antimicrob Chemother, 67 : 1170e5.
Koulenti D,Xu E,Yin Sum Mok I .2019 ."Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. , 7(10) : 386.
File TM,Goldberg L,Das A .2019 .Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis, 69(11) : 1856-1867.
Alexander E,Goldberg L,Das AF .2019 .Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial [published online ahead of print, 2019 Sep 27]. , 322(17) : 1661-1671.
Sandrockc . .Safety and Tolerability of Lefamulin vs Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia: Results of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Double-Blind Noninferiority Phase-3 Clinical Trials. Chest Annual Meeting 2019 Oct 19-23, : .
Zhang L,Wicha WW,Bhavnani SM,Rubino CM SM .2019 .Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods. J Antimicrob Chemother, 74(Suppl 3) : iii27-iii34.
Wicha WW,Strickmann DB,Paukner S. .2019 .Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother, 74(Suppl 3) : iii11-iii18.
Wicha WW,Prince WT,Lell C,Heilmayer W,Gelone SP .2019 .Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother, 74(Suppl 3) : iii19-iii26.
. .Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia. The Medical Letter on Drugs and Therapeuticus. The Medical Letter 2019 (From issue 1581)., : .
Zeitlinger M,Schwameis R,Burian A .2016 .Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother, 71(4) : 1022-1026.
Therapeutics Announces European Medicines Nabriva,Therapeutics US .2020 .AnnouncesEuropean-Medicines-Agency-EMA-Validation-of-MarketingAuthorization-Application-for-Lefamulin. May, : .
Golan Yoav,Infections Skinstructure .2019 .Current Treatment Options for Acute Skin. Clinical Infectious Diseases, 68(S3) : S206-12.
Current Our,Therapeutics Pipeline: Lefamulin. Nabriva .2019 .. Accessed 5 September, : .
GG Briggs .2020 .Novel drugs approved in 2019. MDedgeObGyn. 27 March, : .